Detailed Narrative
Renal Segment: A New Growth Engine
The Renal business emerged as the standout performer in FY25, growing 60% to surpass ₹150 crores in revenue. Management expects this momentum to continue with a 50% growth target for FY26, aiming to add ₹75 crores to the top line. The company plans to sell 500-600 dialysis machines this year, up from 350 in FY25, leveraging its 'Make in India' status to gain market share from established players like Fresenius and Nipro. Service infrastructure is being scaled with 30+ engineers to provide a competitive edge over Chinese importers who lack local support.
Domestic Market Bullishness vs. Export Caution
Polymed is pivoting its growth focus toward the domestic market, guiding for an aggressive 30-32% growth in FY26. This follows a strong recovery in the latter half of FY25 where domestic growth accelerated to 23-24% after a slow start. Conversely, export guidance has been tempered to 12-15% due to geopolitical 'flux' and a slowdown in Southern Europe. Despite this, management believes India is well-positioned to capture long-term market share as US and European customers seek alternatives to China.
Aggressive R&D and Capacity Expansion
The company is significantly ramping up its innovation engine, planning to increase R&D headcount from 70 to over 100 people this year. After launching 30 products in FY25, Polymed aims to add another 50-60 products over the next three years, particularly in high-margin verticals like Cardiology and Critical Care. To support this, a ₹500 crore Capex plan is underway to build three new manufacturing facilities in Haryana, Uttarakhand, and Rajasthan, with commercialization expected by the end of 2026.
Strategic Capital Allocation and M&A
Following a successful QIP, Polymed holds a cash balance of approximately ₹1,100 crores. While ₹500 crores is committed to organic Capex, the remaining capital is being preserved for strategic M&A opportunities in technology-led medical device companies. This focus on capital conservation for growth is the primary reason for the reduction in the dividend payout ratio to 10%. Management is actively scouting for technologies in Cardiology, Critical Care, and Renal portfolios that can be scaled globally.